HK1034033A1 - Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis. - Google Patents

Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis.

Info

Publication number
HK1034033A1
HK1034033A1 HK01102292A HK01102292A HK1034033A1 HK 1034033 A1 HK1034033 A1 HK 1034033A1 HK 01102292 A HK01102292 A HK 01102292A HK 01102292 A HK01102292 A HK 01102292A HK 1034033 A1 HK1034033 A1 HK 1034033A1
Authority
HK
Hong Kong
Prior art keywords
incidence
reducing
fatty acids
polyunsaturated fatty
necrotizing enterocolitis
Prior art date
Application number
HK01102292A
Other languages
English (en)
Inventor
Susan E Carlson
Debra L Ponder
Michael B Montalto
Margaret H Dohnalek
John D Benson
David A Borror
David V Diodato
Original Assignee
Abbott Lab
Univ Tennessee Res Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1034033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/943,576 external-priority patent/US6080787A/en
Application filed by Abbott Lab, Univ Tennessee Res Corp filed Critical Abbott Lab
Publication of HK1034033A1 publication Critical patent/HK1034033A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
HK01102292A 1997-02-21 2001-03-29 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis. HK1034033A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis
PCT/US1998/003235 WO1998036745A2 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Publications (1)

Publication Number Publication Date
HK1034033A1 true HK1034033A1 (en) 2001-10-12

Family

ID=27420004

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01102292A HK1034033A1 (en) 1997-02-21 2001-03-29 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis.

Country Status (24)

Country Link
US (1) US6306908B1 (xx)
EP (1) EP1039892B1 (xx)
JP (1) JP2001516343A (xx)
CN (1) CN1200701C (xx)
AT (1) ATE265207T1 (xx)
AU (1) AU732903B2 (xx)
BR (1) BR9807443A (xx)
CA (1) CA2281706C (xx)
DE (1) DE69823548T2 (xx)
DK (1) DK1039892T3 (xx)
ES (1) ES2219871T3 (xx)
HK (1) HK1034033A1 (xx)
HU (1) HUP0300236A3 (xx)
ID (1) ID22744A (xx)
IL (1) IL131126A (xx)
NO (1) NO994052L (xx)
NZ (1) NZ337039A (xx)
PL (1) PL343902A1 (xx)
PT (1) PT1039892E (xx)
RU (1) RU2199317C2 (xx)
SK (1) SK112399A3 (xx)
TR (1) TR199902023T2 (xx)
TW (1) TWI230607B (xx)
WO (1) WO1998036745A2 (xx)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
US20090274660A1 (en) * 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
US6596302B2 (en) 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
EP1542670B2 (en) * 2002-09-24 2023-07-05 Suntory Holdings Limited Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
PT1638414E (pt) * 2003-06-23 2009-07-13 Nestec Sa Fórmula para lactentes ou fórmula de transição
CA2530170A1 (en) * 2003-06-24 2005-01-06 University Of Kansas Medical Center Infant formula
CH698539A8 (de) 2003-08-18 2009-10-15 Btg Int Ltd Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose.
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
WO2005122791A2 (en) * 2004-06-22 2005-12-29 N.V. Nutricia Improvement of barrier integrity in hiv patients with fatty acids
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
CA2605960A1 (en) * 2005-04-21 2006-10-26 N.V. Nutricia Nutritional supplement for hiv patients
JP5566603B2 (ja) 2005-05-23 2014-08-06 マサチューセッツ インスティテュート オブ テクノロジー Ｐｕｆａを含有する組成物及びそれを使用した方法
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
US20070166354A1 (en) * 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
WO2007059431A1 (en) 2005-11-14 2007-05-24 The Trustees Of Columbia University In The City Of New York Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
US20110136732A1 (en) * 2005-12-23 2011-06-09 N.V. Nutricia Infant nutritional compositions for preventing obesity
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US7867542B2 (en) * 2006-11-02 2011-01-11 Ach Food Companies, Inc. Non-flammable release composition
US9254275B2 (en) * 2007-09-17 2016-02-09 Cornell University Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
AU2008309140B9 (en) † 2007-10-09 2013-07-04 Frutarom Limited Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation
UY31410A1 (es) * 2007-10-30 2009-05-29 Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
BRPI0818723B1 (pt) 2007-11-01 2020-02-27 Enzymotec Ltd. Composição para nutrição infantil
WO2009085388A2 (en) 2007-12-20 2009-07-09 Abbott Laboratories Stable nutritional powder
US8361534B2 (en) * 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
EP2100897A1 (en) 2008-01-30 2009-09-16 BNLfood Investments SARL Lecithin based composition and its use in food
WO2009096772A1 (en) * 2008-02-01 2009-08-06 N.V. Nutricia Composition for stimulating natural killer cell activity
US9737213B1 (en) * 2009-03-24 2017-08-22 Vioptix, Inc. Using an oximeter probe to detect intestinal ischemia
CA2755077A1 (en) * 2009-04-01 2010-10-07 Nestec S.A. Reduction of risk of obesity
TW201112967A (en) * 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (zh) * 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
AU2010329990B2 (en) * 2009-12-08 2015-07-16 Nestec S.A. Infant formula with probiotics and milk fat globule membrane components
DK2525811T4 (en) * 2010-01-19 2019-04-08 Abbott Lab COMPOSITION, INCLUDING LACTOBACILLUS RHAMNOSUS HN001 AND PREBIOTICS FOR USE IN TREATMENT OF ALLERGIC LUNG DISEASE
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
PE20121729A1 (es) 2010-01-29 2013-01-16 Abbott Lab Emulsiones nutricionales que comprenden beta-hidroxi-beta-metilbutirato (hmb) de calcio
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2397038A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Early programming of brain function through soy protein feeding
WO2012009426A1 (en) 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2422629A1 (en) 2010-08-23 2012-02-29 Abbott Laboratories Methods for enhancing cognition and/or memory using maltodextrins
WO2012027287A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Nutritional products including pea protein hydrolysates
CN103153095B (zh) 2010-08-24 2015-07-22 雅培制药有限公司 具有改良感官特性的营养产品
CN103260440B (zh) 2010-12-29 2017-03-29 雅培制药有限公司 包括含有甘油单酯的脂肪***的营养型产品
CA2822660C (en) 2010-12-31 2021-09-07 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides
MX352040B (es) 2010-12-31 2017-11-07 Abbott Lab Formulaciones nutricionales que incluyen los oligosacaridos de leche humana y los acidos grasos poliinsaturados de cadena larga y usos de las mismas.
CN107510040A (zh) 2010-12-31 2017-12-26 雅培制药有限公司 包含人乳低聚糖和核苷酸的营养型组合物以及其治疗和/或预防肠病毒感染的用途
CN103379908B (zh) 2010-12-31 2020-02-14 雅培制药有限公司 使用人乳寡糖、维生素c和抗炎剂减少氧化应激的发病率的方法
EP2658546B1 (en) 2010-12-31 2018-12-05 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
WO2012092156A1 (en) 2010-12-31 2012-07-05 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
EP3338784B1 (en) 2010-12-31 2020-07-22 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
EP3335576A1 (en) 2010-12-31 2018-06-20 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
WO2013012989A2 (en) 2011-07-19 2013-01-24 The Trustees Of Columbia University In The City Of New York Method and system for production of hydrogen and carbon monoxide
US11446316B2 (en) 2011-07-22 2022-09-20 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN113662199A (zh) 2011-08-29 2021-11-19 雅培制药有限公司 用于预防胃肠道损伤和/或促进胃肠道愈合的人乳寡糖
MX2014008023A (es) 2011-12-29 2014-12-08 Abbott Lab Metodos para reducir la contaminacion microbiana de composiciones nutritivas en polvo mezcladas en seco.
WO2013101516A1 (en) 2011-12-29 2013-07-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna
US20150064220A1 (en) 2012-03-27 2015-03-05 Abbott Laboratories Methods for modulating cell-mediated immunity using human milk oligosaccharides
WO2013170189A1 (en) 2012-05-11 2013-11-14 Abbott Laboratories Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
EP2708147B1 (en) 2012-09-14 2020-03-11 Abbott Laboratories Methods for increasing brain functionality using 2-fucosyl-lactose
EP2708146A1 (en) 2012-09-17 2014-03-19 Abbott Laboratories, Inc. Nutritional composition for pregnant women with a beneficial glucose and insulin profile
WO2014078544A1 (en) 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
WO2014099904A1 (en) 2012-12-17 2014-06-26 Abbott Laboratories Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
TW201438719A (zh) 2012-12-18 2014-10-16 Abbott Lab 改善壓力症狀之母乳寡糖
EP2745705A1 (en) 2012-12-18 2014-06-25 Abbott Laboratories Nutritional use of human milk oligosaccharides
WO2014100022A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
ES2708771T3 (es) 2012-12-20 2019-04-11 Abbott Lab Formulaciones nutricionales que usan oligosacáridos de leche humana para modular la inflamación
EP2745708A1 (en) 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20160037817A1 (en) 2013-03-12 2016-02-11 Abbott Laboratories Composition comprising a multifunctional viscosity modifying agent
WO2014144458A1 (en) 2013-03-15 2014-09-18 Abbott Laboratories Methods of maintaining and improving muscle function
MX2015012993A (es) 2013-03-15 2015-12-01 Abbott Lab Composiciones nutricionales que incluyen beta-hidroxi-beta-metilbu tirato de calcio, fosfopeptido de caseina y proteina.
US10070643B2 (en) 2013-03-28 2018-09-11 The Trustees Of Columbia University In The City Of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
SG11201510147VA (en) 2013-06-10 2016-01-28 Abbott Lab Methods and compositions for enhancing cognitive performance
WO2015048646A1 (en) 2013-09-30 2015-04-02 Abbott Laboratories Protein powder
CN104717891A (zh) 2013-10-11 2015-06-17 雅培制药有限公司 用于孕妇的具有有益葡萄糖和胰岛素特征的营养组合物
CN103558296B (zh) * 2013-10-18 2015-03-04 中国农业大学 一种基于脂肪酸检测的动物源性饲料原料鉴别方法
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
WO2015105981A2 (en) 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
EP3673909A1 (en) 2014-04-08 2020-07-01 Abbott Laboratories Nutritional compositions for use in treating enteric infection comprising human milk oligosaccharides
DE102015101273A1 (de) 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
CN109328069B (zh) 2016-04-15 2023-09-01 亿一生物医药开发(上海)有限公司 Il-22在治疗坏死性小肠结肠炎中的用途
RU2665947C1 (ru) * 2017-07-13 2018-09-05 Атикат Магомедхановна Герейханова Способ лечения некротического энтероколита
JP7302032B2 (ja) 2019-06-07 2023-07-03 アボット・ラボラトリーズ 流動特性および消泡特性を有する栄養成分
EP4132560A1 (en) 2020-04-06 2023-02-15 Abbott Laboratories Nutritional formulations for modulating respiratory-induced cytokines
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022177965A1 (en) 2021-02-16 2022-08-25 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en) 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods and compositions for treating gas
WO2023159093A1 (en) 2022-02-16 2023-08-24 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2024064327A1 (en) 2022-09-22 2024-03-28 Abbott Laboratories Human milk oligosaccharides for enhancing blood-brain barrier function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092121B1 (en) 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4950656A (en) 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5043329A (en) 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5116819A (en) * 1989-05-05 1992-05-26 Clintec Nutrition Co. Enteral diet for patients with pulmonary disease
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
DE69231793T2 (de) 1991-01-24 2001-11-08 Martek Corp., Columbia Mikrobielle öle und ihre verwendungen
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
DE4407939A1 (de) * 1993-03-15 1994-09-22 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
CA2201931C (en) 1994-10-05 2004-08-10 Gerhard Kohn Mixture of phospholipid-containing fats and lcp fatty acids
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en) 1996-01-16 1998-08-04 Monolithic System Technology, Inc. Method and structure for improving display data bandwidth in a unified memory architecture system

Also Published As

Publication number Publication date
DK1039892T3 (da) 2004-08-30
AU6176998A (en) 1998-09-09
TWI230607B (en) 2005-04-11
CN1269718A (zh) 2000-10-11
JP2001516343A (ja) 2001-09-25
NZ337039A (en) 2001-06-29
HUP0300236A3 (en) 2003-09-29
DE69823548T2 (de) 2005-02-24
IL131126A0 (en) 2001-01-28
ES2219871T3 (es) 2004-12-01
AU732903B2 (en) 2001-05-03
ID22744A (id) 1999-12-09
PL343902A1 (en) 2001-09-10
ATE265207T1 (de) 2004-05-15
PT1039892E (pt) 2004-09-30
EP1039892B1 (en) 2004-04-28
CA2281706C (en) 2008-08-05
HUP0300236A2 (hu) 2003-06-28
RU2199317C2 (ru) 2003-02-27
WO1998036745A3 (en) 2002-10-03
WO1998036745A2 (en) 1998-08-27
DE69823548D1 (de) 2004-06-03
CA2281706A1 (en) 1998-08-27
SK112399A3 (en) 2000-12-11
US6306908B1 (en) 2001-10-23
NO994052L (no) 1999-10-20
EP1039892A2 (en) 2000-10-04
CN1200701C (zh) 2005-05-11
NO994052D0 (no) 1999-08-23
TR199902023T2 (xx) 2001-09-21
IL131126A (en) 2003-04-10
BR9807443A (pt) 2000-04-25

Similar Documents

Publication Publication Date Title
IL131126A0 (en) Methods and compositions for reducing the incidence of necrotizing enterocolitis
Vidgren et al. Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men
DE69622722D1 (de) Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
DK1121115T4 (da) PUFA-tilskud
EP2255668A3 (en) Production and Use of a Polar Lipid-Rich Fraction Containing Omega-3 and/or Omega-6 Highly Unsaturated Fatty Acids from Microbes, Genetically Modified Plant Seeds and Marine Organisms
PL190841B1 (pl) Syntetyczna kompozycja lipidowa i jej zastosowanie do wytwarzania pokarmu dla niemowląt
NZ331084A (en) Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
NO942365L (no) Lipidisk sammensetning for anvendelse som et næringsmiddel eller i næringsmiddelprodukter
KR940018091A (ko) 불포화 지방산을 포함하는 처방
TW200744463A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
CO5550401A2 (es) Mezclas lipidas y productos alimenticios que contienen acido graso oleico y acidos grasos omega-6 diseñados para aumentar el nivel de lipido intramiocelular
DK1027831T3 (da) Stabiliseret fedtstofsammensætning, fremgangsmåde til fremstilling deraf og ernæringsprodukt indeholdende denne
ATE454820T1 (de) Neuartige fettpulver
Hassam The influence of α-linolenic acid (18: 3ω3) on the metabolism of γ-linolenic acid (18: 3ω6) in the rat
OGUNLEIYE et al. Effect of fish oil and safflower oil in common Japanese diet on human plasma fatty acid composition
Sandoval et al. Omega-3 in the Prevention of Cardiovascular Diseases
Renuka et al. EFFECT OF OMEGA 3 FATTY ACID IN PERIODONTITIS
Cha et al. Effects of α-Linolenic, Eicosapentaenoic and Docosahexaenoic Acids on the Content and Fatty Acid Composition of Brain Phospholipid in Rats
Nettleton Omega-3 and Omega-6 Polyunsaturated Fatty Acids in the American Diet.
Jiang Studies on egg yolk lipids and ovo-cholesterol metabolism.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090219